Exicure

Exicure is a clinical-stage biotechnology company dedicated to developing novel immunomodulatory and gene regulatory drugs targeting validated targets. Exicure's proprietary Spherical Nucleic Acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in various cells and tissues. Exicure’s lead programs focus on inflammatory diseases, genetic disorders, and oncology. SNA constructs demonstrate unparalleled transfection efficiency across multiple cell and tissue types, including skin without the need for carriers or transfection agents. Additionally, SNAs can serve as potent immunotherapeutic agents for treating cancer or infectious diseases.